GILD will be active in developing a portfolio of products effective in treating solid tumors. The specific products and indications will be developed here when transcript becomes available; gastro-intestine, pancreatic and lung cancer mentioned in particular during Q&A in 40-45' time frame of cc.
A question related to acquisitions of small or mid cap companies was basically punted to another time.
News 
Market Data 
Discover 
